Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42391

TYK2 is an intracellular kinase that mediates signalling of key cytokines involved in the pathogenesis of SLE. Consequently, its inhibition by deucravacitinib, a first-in-class oral, selective, allosteric inhibitor of TYK2, could address a persisting unmet need for improved therapies for SLE. To this end, Morand, et al. assessed the efficacy and safety of deucravacitinib in adult patients with SLE.